Par Pharmaceutical sued for patent infringement

Biotech company United Therapeutics Corporation has filed a complaint against US-based Par Pharmaceutical for infringement of patents covering Remodulin (treprostinil sodium).

Remodulin is a treatment for pulmonary arterial hypertension.

Patents involved in the case are US numbers 8,497,393; 9,199,908; 7,999,007; 8,653,137; and 8,658,694.

The claim, which was filed in the US District Court for the District of Delaware on November 17, arose after Par submitted an Abbreviated New Drug Application (ANDA) to the Food and Drug Administration (FDA) seeking approval to sell a generic version of the drug.

Par notified United Therapeutics in October that it had submitted an ANDA.

United Therapeutics has asked the court for a judgment that Par has infringed the five patents covering the drug.

It has also sought to prevent Par from bringing the generic version to market prior to the expiration of the patents, as well costs and expenses.